Close Menu

NEW YORK – Ansa Biotechnologies said on Monday that it has raised $7.9 million in an oversubscribed seed funding round.

Horizon Ventures led the round, with participation from Mubadala Capital, Humboldt Fund, and additional investors.

Together with a pre-seed round in late December 2018 led by Fifty Years, Ansa has raised $9.2 million in total.

The latest funding will allow the company to accelerate development of its DNA synthesis technology, hire staff, build an R&D facility, and establish industrial partnerships.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.